COMP <GO>
HBIO vs JNJ // OPERATING MARGIN
Harvard Bioscience Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HBIO 2
— JNJ 8
▲ OPERATING MARGIN LEADER: JNJ
LAST: $8.80 (+4.51%) • MKT CAP: $40.1M
operating-margins
-56.10%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HBIO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HBIO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.70% | 67.90% | -10.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.66% | 2.97% | +10.69 | HBIO | /fcf-yield <GO> |
| Operating Margin ACTIVE | -56.10% | 34.70% | -90.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -8.10% | 6.00% | -14.10 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.8 | 62.1 | +6.68 | HBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.1M | $662.49B | -$662.45B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HBIO REV | JNJ REV | HBIO GROSS % | JNJ GROSS % | HBIO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $86.5M | $94.19B | 57.7% | 67.9% | $5.5M | $19.70B |
| FY 2024 | $94.1M | $88.82B | 58.2% | 69.1% | -$1.2M | $19.84B |
| FY 2023 | $112.3M | $85.16B | — | — | $14.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HBIO // BETA —
JNJ // BETA 1.08